Analyse moyen terme - BIOMERIEUX : La moyenne mobile, haussière, confirme notre avis.
La tendance haussière précédente a été invalidée, mais le seuil vient d'être réintégré. C'est sans doute un faux signal. La tendance est probablement toujours haussière. Ceci sera confirmé par le franchissement de 79,46 €. Le prochain objectif est à 86,43 €. Le niveau d'invalidation est sous 59,94 €.Arguments :
- La résistance est atteinte, la réaction des prix est insuffisante pour modifier notre avis.
- La moyenne mobile, haussière, confirme notre avis.
Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.